Publications by authors named "Robert M Berman"

Claim this Profile
A
A retrospective analysis of ketamine intravenous therapy for post-traumatic stress disorder in real-world care settings.
Lynne Alison McInnes, Robert Mark Berman, Matthew Worley, Emily Shih

Psychiatry Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models.
Yashika Bansal, Corey Fee, Keith A Misquitta, Sierra A Codeluppi, Etienne Sibille, Robert M Berman

Complex Psychiatry· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Ann W Silk, Biren Saraiya, Roman Groisberg, Nancy Chan, Kristen Spencer, Robert M Berman

Eur J Med Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym.
Diane M Longo, Lisl K M Shoda, Brett A Howell, Vladimir Coric, Robert M Berman

Toxicol Sci· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV-0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers.
Irfan Qureshi, Meghan Lovegren, Victoria Wirtz, Richard Larouche, Mario Tanguay, Robert M Berman

Clin Pharmacol Drug Dev· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers.
Holly D Soares, Maciej Gasior, Jeremy H Toyn, Jun-Sheng Wang, Quan Hong, Robert M Berman

J Pharmacol Exp Ther· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
Vladimir Coric, Stephen Salloway, Christopher H van Dyck, Bruno Dubois, Niels Andreasen, Robert M Berman

JAMA Neurol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of "Word" vs. "Picture" Version of the Free and Cued Selective Reminding Test (FCSRT) in Older Adults.
Molly E Zimmerman, Mindy J Katz, Cuiling Wang, Leah C Burns, Robert M Berman

Alzheimers Dement (Amst)· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
J Craig Nelson, Zia Rahman, Kimberly K Laubmeier, James M Eudicone, Robert D McQuade, Robert M Berman

CNS Spectr· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Anita H Clayton, Ross A Baker, John J Sheehan, Zachary J Cain, Robert A Forbes, Robert M Berman

BMC Res Notes· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Thomas D Stewart, Ainslie Hatch, Kimberly Largay, John J Sheehan, Sabrina V Marler, Robert M Berman

J Affect Disord· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, double-blind, placebo-controlled trials.
David L Dunner, Kimberly K Laubmeier, George Manos, Robert A Forbes, Ross A Baker, Robert M Berman

Prim Care Companion CNS Disord· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies.
Tanya J Fabian, Zachary J Cain, Diane Ammerman, James M Eudicone, Yan Tang, Robert M Berman

Prim Care Companion CNS Disord· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening for predementia AD: time-dependent operating characteristics of episodic memory tests.
Carol A Derby, Leah C Burns, Cuiling Wang, Mindy J Katz, Molly E Zimmerman, Robert M Berman

Neurology· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Charles F Albright, Randy C Dockens, Jere E Meredith, Richard E Olson, Randy Slemmon, Robert M Berman

J Pharmacol Exp Ther· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, Shu-Pang Huang, Randy Slemmon, Robert M Berman

Br J Clin Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Alzheimer's disease phase II clinical trials.
Barry D Greenberg, Maria C Carrillo, J Michael Ryan, Michael Gold, Kim Gallagher, Robert M Berman

Alzheimers Dement· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Vladimir Coric, Christopher H van Dyck, Stephen Salloway, Niels Andreasen, Mark Brody, Robert M Berman

Arch Neurol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.
Gary Tong, Lorna Castaneda, Jun-Sheng Wang, Oleksandr Sverdlov, Shu-Pang Huang, Robert M Berman

Clin Drug Investig· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies.
Maurizio Fava, Christina M Dording, Ross A Baker, Raymond Mankoski, Quynh-Van Tran, Robert M Berman

Prim Care Companion CNS Disord· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Randy Dockens, Jun-Sheng Wang, Lorna Castaneda, Oleksandr Sverdlov, Shu-Pang Huang, Robert M Berman

Clin Pharmacokinet· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
James Craig Nelson, Michael E Thase, Elizabeth E Bellocchio, Linda M Rollin, James M Eudicone, Robert M Berman

Int Clin Psychopharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, Shu-Pang Huang, Randy Slemmon, Robert M Berman

Clin Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjunctive aripiprazole for depression: predictive value of early assessment.
David J Muzina, Jessie S Chambers, Trixia A Camacho, James M Eudicone, Robert A Forbes, Robert M Berman

Am J Manag Care· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.
Robert M Berman, Michael E Thase, Madhukar H Trivedi, James A Hazel, Sabrina Vogel Marler

Neuropsychiatr Dis Treat· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis